Skip to Late-Breaking Abstracts »
All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Poster Presentation Dates
All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.
Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.
| # | Type | Title | Authors | Category | Keywords |
|---|---|---|---|---|---|
| 313 | Poster Presentation | A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms | Manish Patel, MD; Jason J. Luke, MD; Erika P. Hamilton, MD; Bartosz Chmielowski, MD, PhD; George R. Blumenschein, Jr., MD; Hedy L. Kindler, MD; Shakeela Bahadur, MD; Cesar A. Santa-Maria, MD, MSCI; Janine Koucheki; Jichao Sun, PhD; Sanjeev Kaul, PhD; Francine Z. Chen, MD; Xiaoyu Zhang; John J. Muth; Patrick Kaminker, PhD; Paul A. Moore, PhD; Bradley J. Sumrow, MD; Susanna Ulahannan, MD, MMED; | In-Progress Clinical Trials | Antibody; Bispecifics; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy |
| 315 | Poster Presentation | W0180 novel anti-VISTA antibody: Rationale for target patient population and first-in-human trial design in monotherapy and in combination with anti-PD1 antibody | Ignacio J. Melero, Dr., MD, PhD; Carlos A. Gomez-Roca, MD; Pierre Ferre, VetMD, PhD; Pierre Ferre, VetMD, PhD; Eric Chetaille; Aurelie Petain; Celine Thuilliez; Isabelle Vandenberghe; Francisco Cruzalegui, PhD; Asmaa Boudribila; Mariya Pavlyuk; Aurelien Marabelle, MD, PhD; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical trial; Immune contexture; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor microenvironment |
| 316 | Poster Presentation | EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A | Aurelien Marabelle, MD, PhD; Christiane Jungels, MD; Johann S. De Bono, MD; Norbert Vey, MD; Martin Wermke, MD; Elena Garralda, MD; Aude de Gassart, PhD; Patrick Brune; Emmanuel Valentin, PhD; Marina Iché; Daniel OLIVE, M.D., Ph.D.,; Paul Frohna, MD, PharmD, PhD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Cytokine; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 317 | Poster Presentation | A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors | Leisha A. Emens, MD, PhD; Muralidhar Beeram, MD; Erika P. Hamilton, MD; Sarina A. Piha-Paul, MD; Valerie Odegard, PhD; Sue Hamke; Naomi Hunder, MD; Samuel J. Klempner, MD; | In-Progress Clinical Trials | Antibody; Clinical study; Clinical trial; Dendritic cell; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; TLR; Tumor antigens |
| 318 | Poster Presentation | Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation and/or homologous recombination repair deficiency: KEYLYNK-007 | Timothy A. Yap, MD, PhD; Mallika Dhawan; Andrew E. Hendifar; Michele Maio, MD; Taofeek K. Owonikoko; Miguel Quintela-Fandino; Ronnie Shapira-Frommer, MD; Sanatan Saraf, MD; Ping Qiu, PhD; Fan Jin, MD; Alexander Gozman; Douglas A. Levine; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical trial; Gene expression; Solid tumors; Targeted therapy |
| 319 | Poster Presentation | Phase II trial of immunotherapy in primary glioblastoma: antigens from self-renewing autologous tumor cells presented by autologous dendritic cell vaccine | Daniela Bota, MD, MD., PhD; David E. Piccioni, MD, PhD; Christopher M. Duma, MD; Renato V. LaRocca, MD; Santosh Kesari, MD, PhD; Jose A. Carrillo, MD; Robert O’Donnell; Robert Aiken, MD; Frank Hsu; Xiao-Tang Kong; Thomas H. Taylor, PhD; Gabriel I. Nistor, MD; Robert O. Dillman, MD; Daniela Bota, MD, MD., PhD; | In-Progress Clinical Trials | Clinical trial; Dendritic cell; Immune monitoring; Neoantigens; Stem cell/cancer-initiating cell |
| 320 | Poster Presentation | Phase IIa Study of Alpha-DC1 Vaccine against HER2/HER3, Chemokine Modulation Regimen and Pembrolizumab in Patients with Asymptomatic Brain Metastasis from Triple Negative or HER2+ Breast Cancer | Shipra Gandhi, MD; Peter A. Forsyth, MD; Mateusz Opyrchal, MD, PhD; Kamran A. Ahmed, MD; Hung T. Khong, MD; Kristopher Attwood, PhD; Ellis G. Levine, MD; Tracey L. O'Connor, MD; Amy P. Early, MD; Robert A. Fenstermaker, MD; Dheerendra Prasad, MD; Kazuaki Takabe, MD,PhD; Brian J. Czerniecki, MD,PhD; Pawel Kalinski, MD, PhD; | In-Progress Clinical Trials | Checkpoint blockade; Chemokine; Clinical trial; Vaccine |
| 321 | Poster Presentation | Phase I clinical trial assessing the combination of systemic chemokine modulatory regimen targeting TLR3 with neoadjuvant chemotherapy in triple negative breast cancer | Shipra Gandhi, MD; Mateusz Opyrchal, MD, PhD; Cayla Ford; Victoria Fitzpatrick; Melissa Grimm, PhD; Per H. Basse, MD, PhD; Marie Quinn, MD; Agnieszka Witkiewicz, MD; Kristopher Attwood, PhD; Marc S. Ernstoff, MD; Tracey L. O'Connor, MD; Amy P. Early, MD; Ellis G. Levine, MD; Pawel Kalinski, MD, PhD; | In-Progress Clinical Trials | Chemokine; Chemotherapy; Clinical trial; Immune adjuvant; TLR; Tumor infiltrating lymphocytes (TILs) |
| 322 | Poster Presentation | Efficacy and safety of GX-I7 plus pembrolizumab for heavily pretreated patients with metastatic triple negative breast cancer: The Phase 1b/2 KEYNOTE-899 Study. | Joo H. Sohn, PhD; Joo H. Sohn, PhD; Young Hyuk Im; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Cytokine; Immune adjuvant; T cell |
| 323 | Poster Presentation | Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients | Lajos Pusztai, MD; Hailing Lu, MD, PhD; Christopher Hale, PhD; Anne Grosse-Wilde, PhD; Jennifer Specht, MD; Shanu Modi, MD; Hyo Han, MD; Javier Cortes, MD PhD; Mafalda Oliveira, MD, PhD; Phillip Garfin, MD, PhD; Zejing Wang, MD, PhD; Matthew Onsum, PhD; | In-Progress Clinical Trials | Antibody; Biomarkers; Checkpoint blockade; Immune monitoring; Monocyte/Macrophage; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 324 | Poster Presentation | BDB001, a Toll-Like Receptor 7 and 8 (TLR7/8) Agonist, can be safely administered intravenously and shows clinical responses in advanced solid tumors. | Manish Patel, MD; Drew Rasco, MD; Melissa L. Johnson, MD; Anthony W. Tolcher, MD; Lixin Li, PhD; Adam Zong, PhD; Alexander Chung, PhD; Robert H. Andtbacka, MD, CM; | In-Progress Clinical Trials | COVID and Immunotherapy; Adoptive immunotherapy; Clinical study; Clinical trial; Cytokine; Dendritic cell; Monocyte/Macrophage; Solid tumors; TLR |
| 325 | Poster Presentation | Immunotherapy with B cell activating antibody CPI-006 in patients (pts) with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells and memory T effector cells | Gerard J. Criner, MD; Mehrdad Mobasher, MD, MPH; Craig M. Hill, PhD; Shenshen Hu, PhD; Suresh Mahabhashyam, MD, MPH; Joshua Brody, MD; Thomas U. Marron, MD, PhD; Stephen Willingham, PhD; Richard A. Miller, MD; | In-Progress Clinical Trials | COVID and Immunotherapy; Antibody; B cell; Clinical study; Clinical trial; Immune adjuvant; Vaccine |
| 326 | Poster Presentation | SARS-CoV-2 specific T-cells in TIL from patients with epithelial cancer | Pedro Noronha; Georgia Paraschoudi, M.Sc. in Cell and Molecular Biology, Sweden; Eric D. Sousa; Jéssica O. Kamiki; Patrícia A. António; Carolina Condenço; Inês Silva; Andreia Maia, PhD student; Mireia Castillo-Martin; António Beltran; Carlos Carvalho, MD; Joana R. Lerias, PhD; Alimuddin Zumla; Markus J. Maeurer, MD, PhD, FRCP(London); | In-Progress Clinical Trials | COVID and Immunotherapy; Clinical study; Tumor infiltrating lymphocytes (TILs) |
| 327 | Poster Presentation | Study of anti-PD-1 antibody multimodal combination as first-line treatment on time window of advanced solid tumor | Jian Shi, MD; Baoen Shan; Junyan Wang; Jiayin Liu; Rongfeng Liu; Yujie Shan; | In-Progress Clinical Trials | COVID and Immunotherapy; Angiogenesis; Biomarkers; Checkpoint blockade; Chemotherapy; Clinical trial; Gene expression; Immune toxicity; Solid tumors; Targeted therapy |
| 328 | Poster Presentation | Phase 3 study of olaparib ± bevacizumab versus bevacizumab + fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX + bevacizumab (LYNK-003) | Carlos A. Mayo, MD; Ellen B. Gurary; Patricia Marinello; | In-Progress Clinical Trials | Angiogenesis; Chemotherapy; Clinical study; Targeted therapy |
| 329 | Poster Presentation | Prolonged overall survival (OS) in patients with metastatic colorectal cancer (mCRC) in SPICE, a phase I study of enadenotucirev in combination with nivolumab | Tom R. Lillie, MD; Andrew Stone; Sarah Lockwood; Richard R. Brown; Andrew Fox; Eirini Bournazou; John W. Beadle, MBBCH; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| 330 | Poster Presentation | Investigating the clinical safety, efficacy, and immune modulation of combined XL888 and pembrolizumab in metastatic gastrointestinal malignancies | Cameron J. Herting, PhD; Yuchen Zhang; Deon B. Doxie, PhD; Matthew R. Farren, Ph.D.; Michael B. Ware; Olatunji B. Alese, MD; Christina Wu, MD; Walid L. Shaib, MD; Mehmet Akce; Mohammad Y. Zaidi, MD, MS; Amanda N. Ruggieri; Madhav Dhodapkar, MD; Kavita M. Dhodapkar, MD; Juan Sarmiento; Rafi Ahmed, PhD; Shishir K. Maithel; Bassel El-rayes, MD; Gregory B. Lesinski, PhD; | In-Progress Clinical Trials | Checkpoint blockade; Chemokine; Clinical trial; Cytokine; Immune monitoring; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 331 | Poster Presentation | Immunotherapy with Y90-radioembolization for metastatic colorectal cancer (iRE-C) | Pashtoon M. Kasi, MD, MS; Beau M. Toskich, MD; Sandeep T. Laroia, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Inflammation; Neoantigens; Radiotherapy; Solid tumors; Tumor antigens; Tumor microenvironment; Tumor stroma |
| 332 | Oral Presentation | Novel TGF-β signatures in metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab. | Keun-Wook Lee, MD, PhD; Young Suk Park, MD, PhD; Joong Bae Ahn, MD; Jin Kyung Lee, PhD; Jiyeon Ryu, Ph.D; Bitna Oh, MD; Chan-Young Ock, MD, PhD; Sunjin Hwang, MD; Ki Baik Hahm, MD, PhD; Seong-Jin Kim, PhD; Tae Won Kim, MD; Keun-Wook Lee, MD, PhD; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Clinical trial; Tumor microenvironment |
| 333 | Poster Presentation | Targeting the apical intracellular checkpoint CISH unleashes T cell neoantigen reactivity and effector program | Douglas C. Palmer, PhD; Beau R. Webber; Yogin Patel, PhD; Matthew J. Johnson, PhD; Christine M. Kariya; Walker S. Lahr; Maria r. Parkhurst; Jared Gartner, MS; Todd D. Prickett; Frank J. Lowery; Rigel J. Kishton; Devikala Gurusamy; Zulmarie Franco; Suman Vodnala; Miechaleen D. Diers; Natalie K. Wolf; Nicholas J. Slipek; David H. McKenna, Jr., MD; Darin Sumstad; Lydia Viney; Tom Henley; Tilmann Bürckstümmer; Oliver Baker; Ying Hu; Chunhua Yan; Daoud Meerzaman; Kartik Padhan; Winnie Lo; Parisa Malekzadeh; Li Jia; Drew C. Deniger; Shashank J. Patel; Paul F. Robbins; R. Scott McIvor, PhD; Modassir Choudhry; Steven A. Rosenberg; Branden S. Moriarity, PhD; Nicholas P. Restifo; | In-Progress Clinical Trials | Adoptive immunotherapy; Checkpoint blockade; Clinical study; Clinical trial; Neoantigens; Tumor antigens; Tumor infiltrating lymphocytes (TILs) |
| 334 | Poster Presentation | Phase II Study Evaluating a Chemokine-Modulatory (CKM) Regimen in Patients with Colorectal Cancer (CRC) Metastatic to the Liver | Sarbajit Mukherjee, MD, MS; Patrick Boland; Medhavi Gupta; Melissa Grimm, PhD; Kristopher Attwood, PhD; Pawel Kalinski, MD, PhD; | In-Progress Clinical Trials | Chemokine; Clinical trial |
| 335 | Poster Presentation | Novel CoupledCARTM Technology for Treating Colorectal Cancer | Song Li; Chengfei Pu; Zhiyuan Cao; Ning Li; Xinyi Yang; Youli Luo; Haiyan Zhao; Hang Yang; Xi Huang; Xiaogang Shen; Xiuwen Wang; Yongping Song; Junjie Mao; Pengfei Pang; Qun Hu; Zhao Wu; Lei Xiao, Ph.D.; | In-Progress Clinical Trials | Adoptive immunotherapy; Biomarkers; CAR T cells; Clinical study; Gene expression; Inflammation; Solid tumors; T cell; Tumor antigens |
| 337 | Poster Presentation | Pembrolizumab in combination with xelox bevacizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer and a high immune infiltrate: a proof of concept study. FFCD 1703 POCHI | David Tougeron, MD, PhD; Jean Francois Emile; Stephano Kim; Carole Monterymard; marine gilabert; Jérémie BEZ; Astrid Lievre; Laetitia Dahan; Pierre Laurent-puig; Laurent Mineur; ROmain Coriat; Jean Louis Legoux; Vincent Hautefeuille; Jean marc Phelip; Thierry Lecomte; Harry Sokol; Claude Capron; Claire Gallois; Violaine Randrian; Come Lepage; Julien Taieb; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
| 338 | Poster Presentation | Emerging insights on the association of tumor molecular phenotype with clinical benefit in metastatic colorectal cancer (mCRC) subjects treated with AB928 + Modified FOLFOX-6 (mFOLFOX-6) | Akshata R. Udyavar, Ph.D; Michael Cecchini; Daniel DiRenzo, PhD; Sean Cho, PhD; Lisa Seitz, MS; Kristen Zhang, BS; Stephen W. Young, PhD; Amy E. Anderson, PhD; Kimberline Y. Gerrick; Matthew J. Walters, PhD; Houston N. Gilbert, PhD; Olivia S. Gardner; Cheng Quah, MD; Juan C. Jaen, PhD; William Grossman, MD; | In-Progress Clinical Trials | Bioinformatics; Biomarkers; Chemotherapy; Clinical trial; Gene expression; Immune suppression; Metabolism; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 339 | Poster Presentation | Preliminary Safety, Tolerability and Efficacy Results of KN026 (a HER2-targeted Bispecific Antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in Patients (pts) with HER2 aberrated solid tumors | Jifang Gong, MD; Zhi Dong; Dan Liu; June Xu; Jing Yang; Yue Yang; Yakun Qi; Jie Men; Paul Kong; Ting Xu; Lin Shen, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Targeted therapy |
| 340 | Poster Presentation | Phase 1 study of AMG 160, a half-life extended BiTE® (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer | Lisa Horvath; Tanya Dorff, MD; Matthew Rettig, MD; Jean-Pascal Machiels, MD, PhD; Martijn Lolkema, MD, PhD; Karen Autio, MS, MD; Richard Greil; Sylvie Rottey, MD; Nabil Adra, MD, MSc; Mark E. Salvati, PhD; Shirley Poon, MS, MBA; Daniel Tan, MBBS, MRCP; Gabor Jurida; Hosein Kouros-Mehr; Karim Fizazi; Ben Tran, MD; Lisa Horvath; | In-Progress Clinical Trials | Bispecifics; Clinical study; Clinical trial; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| 341 | Poster Presentation | Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC) | Rahul Aggarwal, MD; Dan Costin, MD; Jingsong Zhang, MD, PhD; Paul Monk, MD; Mark Linch, MD; Lawrence I. Karsh, MD; Diane Healey, MS; Stefani Corsi-Travali; Sreenivas Adurthi, PhD; Adedayo Adedoyin; Vincent O'Neill, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Cytokine; Inflammation; Monocyte/Macrophage; Solid tumors; Tumor microenvironment |
| 342 | Poster Presentation | A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk | Toni K. Choueiri; Laurence Albiges, MD; Thomas Powles, MBBS, MD, MRCP; Nehal Mohamed; Fong Wang; Robert J. Motzer, MD; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Coinhibition; Solid tumors; Targeted therapy |
| 343 | Poster Presentation | Phase 3 Study of Pembrolizumab + Docetaxel and Prednisone/Prednisolone for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Pretreated With Next-Generation Hormonal Agents (NHAs) (KEYNOTE-921) | Daniel P. Petrylak, MD; Neal Shore, MD; Mostefa Bennamoun; Raffaele Ratta; Josep M. Piulats; Ben Li; Charles Schloss; Karim Fizazi; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial |
| 344 | Poster Presentation | Phase 3 Trial of Pembrolizumab and Enzalutamide Versus Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641) | Julie Nicole Graff; Joseph Burgents; Li Wen Liang; Arnulf Stenzl; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial |
| 345 | Poster Presentation | Phase 3 Study of Combination Pembrolizumab + Olaparib Therapy Versus Enzalutamide/Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Progression on Chemotherapy (KEYLYNK-010) | Evan Y. Yu, MD; Se Hoon Park; Yi-Hsiu Huang; Mostefa Bennamoun; Lu Xu; Jeri Kim, MD; Emmanuel S. Antonarakis, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial |
| 346 | Poster Presentation | KEYNOTE-991: Phase 3 Study of Pembrolizumab Plus Enzalutamide and Androgen Deprivation Therapy (ADT) for Patients With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Christian Gratzke; Cuizhen Niu; Christian H. Poehlein, MD; Joseph Burgents; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial |
| 347 | Poster Presentation | Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial | Ira Winer, MD, PhD; Lucy Gilbert, MD; Ulka N. Vaishampayan, MD; Seth Rosen, MD; Christopher J. Hoimes, DO; Jameel Muzaffar, MD; Anna Spreafico, MD PhD; David F. McDermott, MD; Quincy Chu, MD; Olivier Dumas, MD; Aman Chauhan, MD; Arvind Chaudhry, MD; Piotr Tomczak, MD; Valentina Boni, MD, PhD; Debora S. Bruno, MD; Kelly K. Curtis, MD; Yan Wang, PhD; Elizabeth Dorn, PhD; Jessicca Rege, PhD; Yangchun Du, PhD; Ilda Bidollari; Lei Sun, PhD; Emily L. Putiri, PhD; Heather C. Losey, PhD; Bruce Dezube, MD; Marc S. Ernstoff, MD; Vamsidhar Velcheti, MD; James Strauss, MD; | In-Progress Clinical Trials | Clinical study; Clinical trial; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 348 | Poster Presentation | A phase 2 umbrella study of retifanlimab (INCMGA00012) alone or in combination with other therapies in patients with advanced or metastatic endometrial cancer (POD1UM-204, GOG 3038, ENGOT-en12/NOGGO) | Brian M. Slomovitz, MD; Bradley J. Monk; Katherine Moxley; Nadeem Ghali; Justyna Fronczek Sokol; Chuan Tian, PhD; Nawel Bourayou, MD; Jalid Sehouli; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical trial; Coinhibition; Targeted therapy |
| 349 | Poster Presentation | Early Safety and Efficacy of a Phase 1/2 Open-Label, Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Alain P. Algazi, MD; William Smith; Timothy Panella; Dong M. Shin, MD; Marie-Louise H. Fjaellskog; John Celebi; Alice Drumheller; Jean Campbell, PhD; Robert H. Pierce, Jr., MD; Michael Guarino; | In-Progress Clinical Trials | Antigen presenting cells; Biomarkers; Checkpoint blockade; Clinical trial; Monocyte/Macrophage; Solid tumors; T cell; Tumor antigens; Tumor microenvironment; Vaccine |
| 351 | Poster Presentation | Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009 | Kevin Harrington, PhD, FRCP, FRCR; Ezra EW. Cohen, MD; Lilian L. Siu, MD; Danny Rischin, MBBS, MD; Lisa Licitra, MD; Jan Vermorken; Quynh-Thu Le, MD, FACR, FASTRO; Makoto Tahara; Jean-Pascal Machiels, MD, PhD; Natalyn Hawk; Joy Ge; Behzad Bidadi, MD, MS; Ramona F. Swaby, MD; Barbara A. Burtness, MD; | In-Progress Clinical Trials | Angiogenesis; Checkpoint blockade; Clinical trial; Targeted therapy |
| 352 | Oral Presentation | Updated clinical data from the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab | Ezra EW. Cohen, MD; Michael Postow, MD; Ryan J. Sullivan, MD; David S. Hong, MD; Heather Yeckes-Rodin, MD; Jerry McCarter, RN, BSN; Nora Zizlsperger; Jeffery Kutok, MD, PhD; Brenda O'Connell, PhD; Kara Page; Jennifer Roberts; Halle Zhang, PhD; Bartosz Chmielowski, MD, PhD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Immune suppression; Immune tolerance; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor microenvironment |
| 353 | Poster Presentation | Safety and efficacy of tumor infiltrating lymphocytes (TIL, LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC | Antonio Jimeno, MD, PhD; Sophie Papa, PhD, MBBS, MRCP; Missak Haigentz, MD; Juan F. Rodríguez-Moreno,, MD; Julian Schardt; Maria Fardis, PhD; Friedrich Graf Finckenstein, MD; Rana Fiaz; Guang Chen; Alex Cacovean; Zelanna Goldberg; Ammar Sukari, MD; | In-Progress Clinical Trials | Adoptive immunotherapy; Checkpoint blockade; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| 354 | Poster Presentation | A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer | Sara I. Pai, MD PhD; Douglas R. Adkins, MD; Lori J. Wirth, MD; Christine H. Chung, MD; Michael K. Gibson, MD PhD; Ammar Sukari, MD; Francis P. Worden, MD; Dimitrios Colevas, MD; Nabil F. Saba, MD; Barbara A. Burtness, MD; Cristina P. Rodriguez, MD; Julie E. Bauman, MD, MPH; Bonnie S. Glisson, MD; Lara A. Dunn, MD; Anish Suri, PhD; Mark Haydock, B.S.; Steven N. Quayle, PhD; Saso Cemerski, PhD; Megan Leader; Jason Brown; Kenneth J. Pienta, MD; Mary C. Simcox, PhD; | In-Progress Clinical Trials | Biomarkers; Clinical trial; Costimulation; Cytokine; Immune monitoring; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor antigens |
| 355 | Poster Presentation | First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies | Nina Shah, MD; Alan Tan, MD; Lihua E. Budde, MD, PhD; Craig C. Hofmeister, MD; Andrew J. Cowan, MD; Hayder Saeed, MD; Jing C. Ye, MD; Mitchell S. Cairo, MD; David A. Rizzieri, MD; Gregory J. Orloff, MD; Xue Snow Ge, PhD; Zachary Lee, PharmD; Neha Dixit, PhD; Wildaliz Nieves, PhD; Mona Vimal, MSc; Haijun Ma, PhD; Takahiro Miyazaki, PhD; Loui Madakamutil, PhD; Mario Q. Marcondes, MD, PhD; Wei Lin, MD; Mary A. Tagliaferri, MD; Jonathan Zalevsky, PhD; Krina K. Patel, MD; | In-Progress Clinical Trials | Biomarkers; Clinical trial; Cytokine; Leukemia/Lymphoma; NK/NK T cell; T cell |
| 356 | Poster Presentation | Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab | Neil L. Berinstein, MD; Isabelle A. Bence-Bruckler; Nick Forward; Pierre Laneuville; Joy Mangel; Douglas Stewart; Irina Amitai; Gail Klein; Nancy Pennell; Iran Rashedi; Kim Roos; Yogesh Bramhecha, PhD; Rebekah Conlon; | In-Progress Clinical Trials | B cell; Checkpoint blockade; Clinical trial; Immune adjuvant; Immune monitoring; Leukemia/Lymphoma; T cell; Targeted therapy; Tumor microenvironment; Vaccine |
| 357 | Poster Presentation | TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma | Sabrina C. Collins, BS; Adarsh Joshi; Lei Shen; Subhasree Das; Kaveri Suryanarayan; Dean C. Bottino; Cheryl Li; Michael Curley; Dannie Wang; Michael Abadier; Ryan Larson; Xavier Parot; | In-Progress Clinical Trials | Biomarkers; Chemokine; Cytokine; Immune contexture; Immune monitoring; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 358 | Poster Presentation | Trial In Progress: A Pilot Study of Combined Immune Checkpoint Inhibition in combination with ablative therapies in subjects with hepatocellular carcinoma (HCC) | Hailey K. Carroll, MD; Umair Aleem, MD; Pooja Varghese; Marie Galligan, PhD; Michèle Bourke; Katherine Hoey; Ronan Ryan, MD; Peter Doran, PhD; Stephen Stewart, MD PhD; Cliona O'Farrelly, PhD; Tim F. Greten, MD; Diarmaid Houlihan, MD; Raymond McDermott, MD; Austin G. Duffy, MD; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Clinical trial; Coinhibition; Immune monitoring; Microbiome; NK/NKT cell; Solid tumors; Targeted therapy; Tumor microenvironment |
| 359 | Oral Presentation | AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results | Hossein Borghaei, MS, DO; Michael Boyer; Melissa L. Johnson, MD; Ramaswamy Govindan, MD; Luis Paz-Ares Rodrigues; Fiona Blackhall; Rene Boosman; Stéphane Champiat; Horst-Dieter Hummel; W. Victoria Lai; Hibiki Udagawa; Anne Chiang; Afshin Dowlati, MD; Christine L. Hann, MD, PhD; Ravi Salgia, MD; Everett E. Vokes, MD; Mukul Minocha; Nooshin Hashemi-Sadraei; Aditya Shetty; Marie-Anne Damiette Smit, MD, MS; Hui Yang; Taofeek K. Owonikoko, MD, PhD; | In-Progress Clinical Trials | Bispecifics; Clinical trial |
| 360 | Poster Presentation | A Phase 1 Study of an Off-the-Shelf, Multi-Neoantigen Vector (ADXS-503) Alone and in Combination with Pembrolizumab in Subjects with Metastatic Non-Small Cell Lung Cancer (NSCLC) | Jonathan W. Goldman, MD; Thomas Stinchcombe, MD; Gregory J. Gerstner, MD; Missak Haigentz Jr., MD; Surya Vangala; Megan Parsi; Victor Kabala; Dinesh Simkhada; Andres A. Gutierrez, MD PhD; Suresh S. Ramalingam, MD; | In-Progress Clinical Trials | Adoptive immunotherapy; Antigen presenting cells; Biomarkers; Checkpoint blockade; Clinical study; Immune tolerance; Neoantigens; Solid tumors; T cell; Tumor antigens |
| 361 | Poster Presentation | A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma - 12 month analysis of biomarkers and clinical outcomes | Magnus Jaderberg, MD; Luis Paz-ares; Susana Cedres; Luis Paz-Ares; Xavier Serres; Charles Ricordel; Nicolas Isambert; Santiago Ponce Aix; Victor Levitsky; Lukasz Kuryk, PhD; Anne-Sophie Moller; Sylvia Vetrhus; | In-Progress Clinical Trials | Clinical study; Gene expression; Immune monitoring; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 362 | Oral Presentation | A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis | James Spicer, PhD, FRCP; Åslaug Helland, MD, PhD; Enric Carcereny, MD; Edurne Arriola, MD, PhD; Manuel Dómine Gomez, MD, PhD; Jose Manuel Trigo Perez, MD, PhD; Jonathan R. Thompson, MD; James Strauss, MD; Ana Laura Ortega Granados, MD; Enriqueta Felip, MD PhD; Emmett V. Schmidt, MD PhD; Michael J. Chisamore, PhD; Noelly Madeleine, PhD; Austin Rayford, MS; Katherine Lorens; Abdul Siddiqui, MD; Hani Gabra, MD, PhD, FRCP; Jaya Nautiyal, PhD; David Micklem, PhD; James B. Lorens, PhD; Matthew G. Krebs, MD, PhD; | In-Progress Clinical Trials | Antigen presenting cells; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Regulatory T cell (Treg cell); Targeted therapy; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 363 | Poster Presentation | Vactosertib and durvalumab as second or later line treatment for PD-L1 positive non-small cell lung cancer: interim result | Byoung Chul c. Cho, MD, PhD; Ki Hyeong Lee, MD, PhD; Ji-Youn Han, MD, PhD; Byoung yong Shim, MD, PhD; Hye Ryun Kim, MD, PhD; Kyoung-Ho Pyo, PhD; Jae-Hwan Kim, PhD; Chung-Feng Xin; Jin Kyung Lee, PhD; Jiyeon Ryu, PhD; Bitna Oh, MD; Sunjin Hwang, MD; Ki Baik Hahm, MD, PhD; Seong-Jin Kim, PhD; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Clinical trial; Coinhibition; Immune monitoring; Solid tumors; Tumor microenvironment |
| 364 | Poster Presentation | A personal neoantigen vaccine NEO-PV-01 in combination with chemotherapy and pembrolizumab induces broad de novo immune responses in first line, non-squamous NSCLC | Mark Awad, MD, PhD; David R. Spigel, MD; Edward B. Garon, MD; Saiama Waqar, MD; Aaron Lisberg, MD; Melissa A. Moles; Jennifer Tepper; April Lamb; Amy Wanamaker; Zakaria Khondker; John Srouji; Jesse Z. Dong; Asaf Poran; Kristen N. Balogh; Meghan Bushway; Mark DeMario, MD; Lakshmi Srinivasan, PhD; Richard B. Gaynor; Ramaswamy Govindan, MD; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Neoantigens; T cell; Tumor antigens; Tumor microenvironment; Vaccine |
| 365 | Poster Presentation | Tumor Treating Fields (TTFields, 150 kHz) concurrent with standard of care treatment for stage 4 non-small cell lung cancer (NSCLC) in Phase 3 LUNAR Study | Ticiana A. Leal, MD; Raphael Bueno; Libor Havel; Jeffrey Ward, MD, PhD; Ticiana A. Leal, MD; | In-Progress Clinical Trials | Checkpoint blockade; Chemotherapy; Clinical trial; Targeted therapy |
| 366 | Poster Presentation | A randomized double-blind placebo-controlled phase III study evaluating perioperative toripalimab combined with platinum-based doublet chemotherapy in resectable stage III NSCLC | Wenxiang Wang; Lin Wu, MD; Wei Zhang; Shun Lu; Haohui Fang; Guohua Yu, MD; Ming Zhou; Wenqun Xing; Qixun Chen; Xingya Li; Nong Yang; Minhua Ye; Wentao Fang; Yunchao Huang; Jichun Liu; Lijie Tan; Xiaosheng Hang; Wengang Zhang; Liwei Zhang; Jun Chen; Xun Zhang; Yu Zhang; Jie Jiang; Aihong Zhong; Shanqing Li; Yunpeng Liu; Guowu Wu; Xiaoyan Kang; Ying Tian; Tao Xu; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Chemotherapy; Clinical trial; Immune adjuvant; Solid tumors; Surgery |
| 367 | Poster Presentation | A Phase 1/1b Dose-escalation Study of Intravenously Administered SB 11285 Alone and in Combination with Atezolizumab in Patients with Advanced Solid Tumors | Jason J. Luke, MD; Filip Janku, MD, PhD; Anthony J. Olszanski, MD, RPh; Kevin Leach; Radhakrishnan Iyer; Atif Abbas, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Cytokine; Immune monitoring; T cell; Tumor microenvironment |
| 368 | Oral Presentation | REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors | Adi Diab, MD; Brendan D. Curti, MD; Mehmet A. Bilen, MD; Andrew S. Brohl, MD; Evidio Domingo-Musibay, MD; Erkut H. Borazanci, MD; Christie Fanton, PhD; Cat Haglund; Mona Vimal, MSc; Mann Muhsin, MD; Mario Q. Marcondes, MD, PhD; Anh Nguyen; Mary A. Tagliaferri, MD; Wei Lin, MD; Jonathan Zalevsky, PhD; Sandra P. D'Angelo, MD; | In-Progress Clinical Trials | Biomarkers; Clinical trial; Cytokine; Solid tumors; T cell; TLR; Tumor microenvironment |
| 369 | Poster Presentation | Safety and pharmacodynamic activity of ATOR-1015, a CTLA-4 x OX40 bispecific antibody, in a phase 1 dose escalation study of patients with advanced solid malignancies | Jeffrey Yachnin, MD, PhD; Gustav J. Ullenhag, PhD, MD; Ana Carneiro, MD PhD; Dorte Nielsen, MD, PhD; Kristoffer Staal Rohrberg, MD, PhD; Anne Månsson Kvarnhammar, PhD; Lena Schultz; Erika Bågeman, PhD; Erika Bågeman; Camilla Wennersten, PhD; Charlotte A. Russell, MD, PhD; | In-Progress Clinical Trials | Antibody; Bispecifics; Checkpoint blockade; Clinical trial; Solid tumors |
| 370 | Poster Presentation | Pharmacodynamic assessment of a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab to patients with advanced solid tumors | Victor Moreno, PhD, MD; Tatiana Hernandez; Ignacio J. Melero, Dr., MD, PhD; Miguel Sanmamed; Iben Spanggaard; Kristoffer Staal Rohrberg, MD, PhD; Josep Tabernero, MD, PhD, MSc.; Analia Azaro; Maria Martinez Garcia; Alejo Rodriguez-Vida; Christina Claus; Florian Heil; Oliver Krieter; Oliver Grimm; Marta Canamero, MD, PhD; Jose Duarte; Alexandra-Cristina Nica; Iakov Davydov; Michael Hettich; Chia-Huey Ooi; Christian Heichinger; Ernesto Guarin; Radoiane Helbaj; Tamara Tanos; Eveline Nueesch; Maurizio Ceppi, PhD; Irene Moreno; Emiliano Calvo; | In-Progress Clinical Trials | Biomarkers; Bispecifics; Checkpoint blockade; Clinical trial; Costimulation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 371 | Poster Presentation | The association of the gut microbiota and clinical response to immune checkpoint inhibitors in patients with advanced cancer | Cheng-Hsun Chiu; Chih-Yu Tsai; Yu-Fen Lin; John W. Chang, MD; Chiao-En Wu; Yuan-Ming Yeh; Yung-Chi Shen; Ming-Mo Hou; Jia-Juan Hsieh; John W. Chang, MD; | In-Progress Clinical Trials | Biomarkers; Clinical study; Microbiome; Solid tumors |
| 372 | Poster Presentation | Single-agent anti-tumor activity in relapsed/refractory solid tumors: interim data from the Phase 1 solid tumor trial of AMV564, a novel T-cell engager | Sarina A. Piha-Paul, MD; Alexander N. Starodub, MD; Raghad Karim, MD; Michael Shafique, MD; Gabriel R. Tinoco Suarez, MD; Curtis Ruegg, PhD; Victoria Smith, PhD; Patrick Chun, MD; | In-Progress Clinical Trials | Bispecifics; Clinical study; Clinical trial; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor microenvironment |
| 373 | Poster Presentation | Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2 | John D. Powderly, II, MD; Bradley C. Carthon, MD Ph.D; Marc S. Ernstoff, MD; Anthony J. Olszanski, MD, RPh; John M. Wrangle, MD; Anthony F. Shields, MD PhD; Sarina A. Piha-Paul, MD; Kelly K. Curtis, MD; Ilda Bidollari; Yangchun Du, PhD; Lei Sun, PhD; Emily L. Putiri, PhD; Yan Wang, PhD; Heather C. Losey, PhD; Bruce Dezube, MD; Bruce Dezube, MD; Ulka N. Vaishampayan, MD; | In-Progress Clinical Trials | Clinical study; Clinical trial; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell |
| 374 | Poster Presentation | A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors | Devalingam Mahalingam, MBBChBAO; Devalingam Mahalingam, MBBChBAO; Wael A. Harb, MD; Amita Patnaik, MD FRCP(C); Susanna Ulahannan, MD, MMED; Haider Mahdi, MD; Manmeet S. Ahluwalia, MD; Manish Patel, MD; Afshin Dowlati, MD; Andrea Bullock, MD; Patrick Wen, MD; Shubham Pant, MD; Mary Mulcahy, MD; Robert Guttendorf, Rph, PhD; Lou Vaickus, MD; Suming Wang, PhD; Marsha Crochiere, PhD; Melanie Vincent, PhD; Michael Cieslewicz, PhD; Jing Watnick, PhD; | In-Progress Clinical Trials | Angiogenesis; Clinical study; Clinical trial; MDSC; Monocyte/Macrophage; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor microenvironment |
| 375 | Poster Presentation | Expansion of HPV-16 specific T cells in patients with HPV-related cancers treated with bintrafusp alfa | Nicole J. Toney, Ph.D; Yo-Ting Tsai, PhD; Claire S. Rumfield, PhD; Samuel T. Pellom, PhD; Caroline Jochems, MD, PhD; Julius Strauss, MD; James L. Gulley, MD, PhD; Jeffrey Schlom, PhD; Renee N. Donahue, PhD; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Tumor antigens; Vaccine |
| 376 | Poster Presentation | A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors | Shubham Pant, MD; Amishi Shah; Pavlos Msaouel, MD, PhD; Matthew T. Campbell, MD; Shi-Ming Tu; Jianjun Gao, MD PhD; George R. Blumenschein, Jr., MD; Frank Mott; Xiuning Le, MD, PhD; Mehmet Altan, MD; Funda Meric-Bernstam, MD; Timothy A. Yap, MD, PhD; Vivek Subbiah, MD; Jordi Rodon; Axel Glasmacher; Imke Mulder; Michael J. Chisamore, PhD; Alexander Stevenson, PhD; Nizar M. Tannir, MD, FACP; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Microbiome; Solid tumors; TLR |
| 377 | Poster Presentation | AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects | Claire H. Galand, PhD; Vignesh Venkatraman; Marilyn D. Marques; James Strauss, MD; Richard D. Carvajal, MD; Min Lim; Benjamin Morin, PhD; Olga Ignatovich, PhD; Mark A. Findeis, PhD; Dennis Underwood, PhD; Marc A. Van Dijk, PhD; Irina Shapiro, PhD; Lernik Ohanjanian, MD, MPH; Anna Wijatyk, MD; Nicholas Wilson, PhD; Jennifer S. Buell, PhD; Dhan Chand, PhD; David Savitsky, PhD; Anthony W. Tolcher, MD; | In-Progress Clinical Trials | Antibody; Clinical trial; Immune monitoring; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 378 | Poster Presentation | A first in-human, multicenter, open-label, dose-finding phase 1 study of the immune stimulator antibody conjugate NJH395 in patients with nonbreast HER2+ advanced malignancies | Filip Janku, MD, PhD; Sae-Won Han; Toshihiko Doi, MD, PhD; Jaffer A. Ajani, MD; Yasutoshi Kuboki; Ping Mahling; Kulandayan Subramanian; Marc Pelletier; Vasileios Askoxylakis, MD, PhD; Salvatore Siena; | In-Progress Clinical Trials | Antibody; Clinical study; Clinical trial; Cytokine; T cell; TLR; Tumor infiltrating lymphocytes (TILs) |
| 379 | Poster Presentation | Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor | David S. Hong, MD; David S. Hong, MD; David S. Hong, MD; Jeffrey M. Clarke, MD; Tanner Johanns; Partow Kebriaei; John V. Heymach, MD, PhD; Ahmed Galal; Samuel Saibil; Adrian Sacher, MD, MSc; Francine Brophy; Gareth Betts, PhD; Natalie Bath, MSc; Spinner William; Alex J. Tipping, PhD; Jessica Tucci; Raymond Luke; Trupti Trivedi, MS; Quan Lin; Jean-Marc Navenot, PhD; Paula M. Fracasso, MD, PhD; Karen Miller, PhD; Elliot Norry, MD; Mark Dudley; Marcus O. Butler, MD; | In-Progress Clinical Trials | Adoptive immunotherapy; Targeted therapy |
| 380 | Poster Presentation | Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors | David Hong, MD; Sandip P. Patel, MD; Manish R. Patel, D.O.; Kimberly Musni, BSHA; Marlisa Anderson, MPH; Sarah Cooley, PhD, MS; Bahram Valamehr, PhD; Wayne Chu, MD; | In-Progress Clinical Trials | Adoptive immunotherapy; Checkpoint blockade; Clinical trial; Leukemia/Lymphoma; NK/NK T cell; Solid tumors |
| 381 | Poster Presentation | Role of CT Scans of Abdomen and Pelvis in Management of Patients with Immunotherapy-induced Colitis | Juan J. Ibarra Rovira, MD; Raghunandan Vikram, MD; Selvi Thirumurthi, MD; Bulent Yilmaz, MD; Heather Lin, MS, PhD; Fechukwu O. Akhmedzhanov, MD, MPH; David S. Hong, MD; Abdulrazzak Zarifa; Melissa Tagart, MD; Funda Meric-Bernstam, MD; Aung Naing, MD, FACP; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Immune toxicity; Inflammation; Targeted therapy |
| 382 | Poster Presentation | Targeting Innate Immunity with BXCL701 in Combination with Pembrolizumab in Patients with Advanced Solid Cancers: Phase 2 Basket Study | Filip Janku, MD, PhD; Apostolia M. Tsimberidou, MD, PhD; Veronica R. Holley; Abha Adat, MD; Ozgur Karakuzu, PhD; Greg Call, PhD; Gabriele Urschel; Diane Healey, MS; Vincent O’Neill; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Inflammation; Solid tumors |
| 383 | Poster Presentation | First-in-man clinical trial of intratumoral injection of Clostridium novyi-NT spores in combination with pembrolizumab in patients with treatment-refractory advanced solid tumors | Filip Janku, MD, PhD; Siqing Fu, MD, PhD; Ravi Murthy, MD; Daniel D. Karp, MD; David S. Hong, MD; Apostolia M. Tsimberidou, MD, PhD; Maura L. Gillison, MD PhD; Abha Adat, MD; Anjali Raina; Greg Call, PhD; Brent L. Kreider; David Tung; Mary Varterasian, MD; Khashayarsha Khazaie, PhD, DSc; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Inflammation; Vaccine |
| 384 | Poster Presentation | A Phase 1 study to evaluate the safety, PK, and antitumor activity of AK117, an anti-CD47 monoclonal antibody, in subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas | Amy AP. Prawira, MD; Jermaine Coward; Anna Mislang, MD; Adnan Nagrial, MD; Hui K. Gan, MBBS PhD; Xiaoping Jin, PhD; Baiyong Li, PhD; Zhongmin Maxwell Wang, PhD; Kon Yew Kwek; Dennis Xia; Yu Xia, PhD; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical trial; Leukemia/Lymphoma; Monocyte/Macrophage; Solid tumors; Tumor antigens; Tumor evasion |
| 385 | Poster Presentation | A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results | Jordan Berlin, MD; Wael A. Harb, MD; Alex A. Adjei, MD PhD; Yan Xing, MD, PhD; Paul Swiecicki, MD; Mahesh Seetharam, MD; Lakshminarayanan Nandagopal, MD; Ajay Gopal, MD; Cong Xu, MD, PhD; Cong Xu, MD, PhD; Yuan Meng, MD; Linda Lee, PharmD; Yonggang Zhao, PhD; Zhengyi Wang, PhD; Joan Huaqiong Shen, MD, PhD; | In-Progress Clinical Trials | Antibody; Clinical study; Clinical trial; Monocyte/Macrophage; Solid tumors |
| 386 | Oral Presentation | Phase I/Ib first-in-human study of HEK-NIZ985, a recombinant IL-15/IL-15Rα heterodimer, alone and in combination with spartalizumab, in adults with advanced and metastatic solid tumors | Rom S. Leidner, MD; Andrea Wang-Gillam, MD, PhD; Sumati Gupta, MD; Robert Wesolowski, MD; Douglas G. McNeel, MD, PhD; Kevin C. Conlon, MD; Nehal S. Parikh, MD; Jessica A. O’Keeffe, PhD; Niladri Roy Chowdhury, PhD; Xiaoli Wang, PhD; Ryan Sullivan, PhD; John A. Thompson, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Cytokine; NK/NK T cell; Solid tumors |
| 387 | Poster Presentation | A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies | Chia-Chi Lin, MD, PhD; Elena Garralda, MD; Patrick Schöffski; David S. Hong, MD; Lillian Siu, MD; Miguel Martin, MD; Michela Maur, MD; Rina Hui, MD; Ross Soo, MD; Joanne Chiu, MD; Tian Zhang, MD; Brigette Ma, MD; Chrisann Kyi, MD; Daniel Tan, MBBS, MRCP; Philippe Cassier, MD; John Sarantopoulos, MD; Andrew Weickhardt, MBBS, FRACP, DMedSc; Rich Carvajal, MD; Jennifer Spratlin, MD; Taito Esaki, MD; Fréderic Rolland; Wallace Akerley, MD; Barbara Deschler-Baier; Catherine A. Sabatos-Peyton, PhD; Niladri Roy Chowdhury, PhD; Daniel Gusenleitner, PhD; Eunice Kwak, MD, PhD; Vasileios Askoxylakis, MD, PhD; Filippo De Braud; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical trial; Coinhibition; Solid tumors |
| 388 | Poster Presentation | Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors | Johanna C. Bendell, MD; Wells Messersmith, MD; Drew Rasco, MD; Andrea Wang-Gillam, MD, PhD; Wungki Park, MD; Lei Zhou, MD, MS; Laura L. Carter, PhD; Jean-Marie Bruey, PhD; Jack Li, PhD; Beatrice Ferguson, MS; Jakob Dupont, MD; Marya F. Chaney, PhD; Johann S. De Bono, MD; | In-Progress Clinical Trials | Clinical trial; Gene expression; Immune contexture; Immune monitoring; Inflammation; MDSC; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 389 | Poster Presentation | Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors | Wells Messersmith, MD; Drew Rasco, MD; Johann S. De Bono, MD; Andrea Wang-Gillam, MD, PhD; Wungki Park, MD; David Nickle, PhD; Anna Galkin, PhD; Beatrice Ferguson, MS; Laura L. Carter, PhD; Lei Zhou, MD, MS; Jakob Dupont, MD; Marya F. Chaney, PhD; Johanna C. Bendell, MD; Jean-Marie Bruey, PhD; | In-Progress Clinical Trials | Biomarkers; Clinical trial; Gene expression; MDSC; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 390 | Poster Presentation | Emerging safety and activity data from GEN-009-101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors | Maura L. Gillison, MD PhD; Roger B. Cohen, MD; Przemyslaw Twardowski, MD; Ammar Sukari, MD; Melissa L. Johnson, MD; Rudy Lackner, MD; Thomas A. Davis, MD; Thomas A. Davis, MD; Arthur P. DeCillis, MD; Richard Hernandez; Jessica Price; Kevin J. Mancini, MS; Mara G. Shainheit, PhD; Jessica B. Flechtner, PhD; Mark Awad, MD, PhD; Mark Awad, MD, PhD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine |
| 391 | Poster Presentation | A first-in-human study of intratumoral SAR441000, an mRNA mixture encoding IL-12sc, interferon alpha2b, GM-CSF and IL-15sushi as monotherapy and in combination with cemiplimab in advanced solid tumors | Oliver Bechter, MD; Jochen Utikal, MD; Jean-Francois Baurain, MD; Christophe Massard, MD; Ugur Sahin, MD; Evelyna Derhovanessian; Marie-Laure Ozoux, Phd; Rahul Marpadga, MD; Esteban-Rodrigo Imedio, MD; Nicolas P. Acquavella, MD; Carmen Loquai, MD; | In-Progress Clinical Trials | B cell; Checkpoint blockade; Clinical trial; Costimulation; Cytokine; Immune toxicity; RNA; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| 392 | Poster Presentation | Phase 1 Study of CI-8993 anti-VISTA antibody in patients with advanced solid tumor malignancies | Elizabeth Martinez, PhD/DHA, MSN, HCC,; Jason Faris, MD; Reinhard Von Roemeling, MD; Steven Angelides; Melissa L. Johnson, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Monocyte/Macrophage; Solid tumors; T cell; Targeted therapy; Tumor microenvironment; Tumor stroma |
| 393 | Poster Presentation | First-in-human phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: initial phase 1 results | Claire F. Friedman, MD; Paolo A. Ascierto, MD; Diwakar Davar, MD; Mark O'Hara, MD; Ronnie Shapira-Frommer, MD; Matthew Dallos, MD; Vivek Khemka, MD, MBA; Lee James, MD, PhD; Bruce S. Fischer, MD; Shilpa Demes, PhD; Li Li, PhD; Martin Kozicki, MBC; Palanikumar Ravindran, PhD; Ke Xu, PhD; Georgia Kollia, PhD; Jacqueline Shoukry, MBS; Mona Yunan, BA; Ashish Massey, MD, PhD; Martin Gutierrez, MD; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| 394 | Poster Presentation | Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results | Diwakar Davar, MD; Matteo Simonelli, MD; Martin Gutierrez, MD; Emiliano Calvo, MD PhD; Jason Melear, MD; Sarina A. Piha-Paul, MD; Donald Richards, MD, PhD; Matthew Dallos, MD; Janaki Parameswaran, MD; Vinit Kumar, PhD; Xiaochen Zhao, PhD; Santanu Dutta, PhD; Ignacio J. Melero, MD, PhD; | In-Progress Clinical Trials | Antibody; Biomarkers; Checkpoint blockade; Chemokine; Clinical trial; Cytokine; MDSC; Myeloid cells; Solid tumors; Tumor microenvironment |
| 395 | Poster Presentation | A first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, in patients with advanced cancer and resistance to PD-(L)1 therapy | Timothy A. Yap, MD, PhD; Deborah J. Wong, M.D., Ph.D.; Siwen Hu-Lieskovan, PhD, MD; Kyriakos P. Papadopoulos, MD; Michelle Morrow, PhD; Michelle Morrow, PhD; Urszula Grabowska, PhD; Daniel Gliddon, PhD; Josefin-Beate Holz, MD, PhD; Patricia LoRusso, DO; | In-Progress Clinical Trials | Antibody; Bispecifics; Checkpoint blockade; Clinical trial; Coinhibition; T cell |
| 396 | Poster Presentation | Overcoming resistance to anti-PD-1 with tumor agnostic NBTXR3: from bench to bed side | James W. Welsh, MD; Colette Shen; Jessica Frakes, MD; Jiaxin Niu, MD, PhD; Jared Weiss, MD; Jimmy Caudell, MD; Hu Yun, PhD; Hampartsoum Barsoumian, PhD; Juliette Thariat, MD, PhD; Sylvie Bonvalot, MD; Zsusanna Papaï; Maria Angelica Cortez, PhD; Ping Zhang, PhD; Katherine L. Jameson, PhD; Patricia Said; Sébastien Paris; Tanguy Seiwert, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Radiotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 397 | Poster Presentation | Intra-Tumor Immunotherapy Injections utilizing Image guidance in Interventional Radiology: Clinical Trial Experience at a Tertiary care Cancer Center | Ravi Murthy; Rahul A. Sheth, MD; Alda Tam; Sanjay Gupta; Vivek Subbiah, MD; Filip Janku, MD, PhD; Timothy A. Yap, MD, PhD; Adi Diab, MD; Aung Naing, MD, FACP; Sapna Patel, MD; Funda Meric-Bernstam, MD; | In-Progress Clinical Trials | Clinical trial; Solid tumors; Vaccine |
| 398 | Poster Presentation | AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy | Steven J. O'Day, MD; Anthony El khoueiry, MD; Chethan Ramamurthy, MD; Andrea Bullock, MD; Irina Shapiro, PhD; Serina Ng, BS; Haiyong Han, PhD; Lernik Ohanjanian Namagerdi, MD, MPH; Remigiusz Kaleta, MD; Anna Wijatyk, MD; Olivia J. Wijatyk; waldo Ortuzar, MD; Marek Ancukiewicz, PhD; Jennifer S. Buell, PhD; Dhan Chand, PhD; Michael S. Gordon; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Solid tumors |
| 399 | Poster Presentation | Cosibelimab, an anti-PD-L1 antibody: Preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial | Dean L. Harris, MD FRACP; Daniel Brungs; Rahul Ladwah; Andrew Mant, MD; Margaret McGrath; Andrea Tazbirkova; Andrey Akopov; Natalia Fadeeva; Boris Kasparov; Nadezhda V. Kovalenko; Vadim Kozlov; Fedor Moiseenko; Vasiliy Oschepkov; Piotr Koralewski; Dariusz Kowalski; Iwona Lugowska; Chaiyut Charoentumn; Arunee Dechaphunkul; Virote Sriuranpong; James Oliviero; Philip R. Clingan; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| 400 | Poster Presentation | CoupledCARTM Technology for Treating Thyroid Cancer | Xingchen Liu; Keshu Zhou; Yong Huang; Chengfei Pu; Zhiyuan Cao; Ruihong Zhu; Haiyang Tang; Zhipeng Huang; Hang Yang; Xi Huang; Yongping Song; Renbin Liu; Zhao Wu; Lei Xiao, Ph.D.; | In-Progress Clinical Trials | Adoptive immunotherapy; Biomarkers; CAR T cells; Clinical study; Gene expression; Inflammation; Solid tumors; T cell; Tumor antigens |
| 401 | Poster Presentation | Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors | Manish R. Sharma, MD; Ecaterina Ileana Dumbrava, MD; Richard D. Carvajal, MD; Daniel V. Catenacci, MD; Leisha A. Emens, MD, PhD; Glenn J. Hanna, MD; Dejan Juric; Yoon-Koo Kang; Jeeyun Lee, MD, PhD; Keun-Wook Lee, MD, PhD; Bob T. Li; Kathleen N. Moore; Mark D. Pegram; Paula R. Pohlmann; Drew Rasco; Alexander I. Spira, MD, PhD, FACP; Antoinette Tan; Ding Wang, MD; Shelley E. Ackerman, PhD; Heidi N. LeBlanc; David Dornan, PhD; Marcin Kowanetz, Ph.D.; Michael N. Alonso, PhD; Edith A. Perez, MD; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical study; Immune adjuvant; Myeloid cells; Solid tumors; T cell; Targeted therapy; TLR; Tumor microenvironment |
| 402 | Poster Presentation | DRAGON: Phase 1 trial of SRK-181, a latent TGFβ1 inhibitor in combination with anti-PD-(L)1 inhibitors for patients with solid tumors unresponsive to anti-PD-(L)1 therapy alone | Johanna C. Bendell, MD; Lu Gan; Johanna C. Bendell, MD; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical study; Solid tumors |
| 403 | Poster Presentation | Early results from a phase 1 study to evaluate safety, pharmacokinetics, and efficacy of AMG 404, a programmed death-1 (PD-1) antibody, in patients with advanced solid tumors | Timothy J. Price, MBBS, DHlthSc (Medicine), FRACP; Sant P. Chawla, MD; Gerald S. Falchook, MD, MS; Hans Prenen, MD; Iwona Lugowska; Vivek Subbiah, MD; Jose Monzon; Yuichi Ozawa; Tobias Arkenau, MD, PhD; Caio S. Rocha Lima, MD; Yasutoshi Kuboki; Tomohiro Nishina; Mun Hui; Erik Rasmussen, PhD; Hansen Wong; Saltanat Najmi; Nooshin H. Sadraei; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Cytokine; Solid tumors |
| 404 | Poster Presentation | ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC) | Keun-Wook Lee, MD, PhD; Hyun C. Chung, MD, PhD; Won Seog Kim, MD; Laura Q. Chow, MD; Nehal Lakhani, MD, PhD; Wells Messersmith, MD; Yung-Jue Bang, MD PhD; Patricia LoRusso, DO; Philip S. Fanning, PhD; Pierre Squifflet, MSc; Feng Jin, PhD; Alison Forgie, PhD; Hong I. Wan, PhD; Jaume Pons, PhD; Sophia S. Randolph, MD, PhD; Justin F. Gainor, MD; | In-Progress Clinical Trials | Antibody; Antigen presenting cells; Checkpoint blockade; Chemotherapy; Clinical trial; Costimulation; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor microenvironment |
| 405 | Poster Presentation | CDX1140-01, a Phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3) | Rachel E. Sanborn, MD; Ralph J. Hauke, MD; Nashat Y. Gabrail, MD; Mark O'Hara, MD; Nina Bhardwaj, MD, PhD; Rodolfo E. Bordoni, MD; Michael S. Gordon; Danny Khalil, MD, PhD; Maen Abdelrahim; Thomas U. Marron, MD, PhD; Thomas Hawthorne; Lawrence J. Thomas, PhD; Tracey Rawls, MA; Mark Rogalski; Diego Alvarado; Laura Vitale, BS; Tibor Keler, PhD; Michael Yellin, MD; | In-Progress Clinical Trials | Antibody; Biomarkers; Clinical trial; Dendritic cell; Leukemia/Lymphoma; Solid tumors; Tumor microenvironment |
| 406 | Poster Presentation | CDX527-01, a phase 1 dose-escalation and expansion study of the PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies | Michael Yellin, MD; Tracey Rawls, MA; Diane C. Young, MD; Philip Golden; Laura Vitale, BS; Li-Zhen He, MD; Lawrence J. Thomas, PhD; Tibor Keler, PhD; | In-Progress Clinical Trials | Antibody; Biomarkers; Bispecifics; Checkpoint blockade; Clinical trial; Costimulation; Solid tumors |
| 407 | Poster Presentation | Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors | Elaine Shum, MD; Adil Daud, MD; Matthew J. Reilley, MD; Yana G. Najjar, MD; John A. Thompson, MD; Joaquina C. Baranda, MD; R. Donald Harvey, PharmD; Rom S. Leidner, MD; Anthony F. Shields, MD PhD; Ezra EW. Cohen, MD; Roger B. Cohen, MD; Alain Mita, MD; Shubham Pant, MD; Mark N. Stein, MD; Bartosz Chmielowski, MD, PhD; Siwen Hu-Lieskovan, MD, PhD; Catherine A. Fleener, MS; Ying Ding, PhD; Sowmya Chollate, MS; Hector Avina; Jolene S. Shorr; Raphael Clynes, MD, PhD; Barbara Hickingbottom, MD; | In-Progress Clinical Trials | Antibody; Biomarkers; Bispecifics; Checkpoint blockade; Clinical study; Clinical trial; Immune toxicity; Solid tumors; T cell |
| 408 | Poster Presentation | Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors | Kevin Harrington, PhD, FRCP, FRCR; Eileen Parkes; Jared Weiss, MD; Mathew Ingham; Andrés Cervantes; Emiliano Calvo, MD PhD; Matthew Riese; Ute Klinkhardt; Patricia Sikken; Michael Schmohl; Elena Garralda, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Coinhibition; Solid tumors |
| 409 | Poster Presentation | A Phase I Trial of Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO) | John H. Stewart, IV, MD, MBA; John H. Strickler, MD; Niharika B. Mettu, MD, PhD; Shannon MacLaughlan, MD; Donna Niedzwiecki, PhD; Edward Levine, MD; Daniel Blazer, MD; | In-Progress Clinical Trials | Clinical trial; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 410 | Poster Presentation | Phase I study of intratumoral NBTXR3 in combination with anti-PD-1 in patients with advanced cancers | Colette Shen; Jessica Frakes, MD; Jiaxin Niu, MD; Jared Weiss, MD; Jimmy Caudell, MD; Katherine L. Jameson, PhD; Patricia Said; Tanguy Seiwert, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Radiotherapy; T cell; Tumor infiltrating lymphocytes (TILs) |
| 411 | Poster Presentation | Novel intratumoral agent, INT230-6 induces cancer cell death, increases tumor infiltrates and results in durable benefit alone or in combination with pembrolizumab in refractory patients | Anthony El-Khoueiry, MD; Jacob Thomas, MD; Anthony J. Olszanski, MD, RPh; Nilofer Azad, MD; Lewis H. Bender, MS, MA, MBA; Ian B. Walters, MD, MBA; Ian B. Walters, MD, MBA; Giles F. Whalen, MD; Diana Hanna, MD; Matthew Ingham, MD; Lilian L. Siu, MD; | In-Progress Clinical Trials | Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Neoantigens; Solid tumors; Tumor antigens; Tumor infiltrating lymphocytes (TILs) |
| 412 | Poster Presentation | First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4-1BB (GEN1046) in patients with advanced solid tumors | Elena Garralda, MD; Ravit Geva, MD; Eytan Ben-Ami; Corinne Maurice-Dror; Emiliano Calvo, MD PhD; Patricia LoRusso, DO; Özlem Türeci; Michelle Niewood; Ugur Sahin; Maria Jure-Kunkel; Ulf Forssmann; Tahamtan Ahmadi; Ignacio J. Melero, MD, PhD; | In-Progress Clinical Trials | Antibody; Bispecifics; Checkpoint blockade; Clinical study; Clinical trial; Coinhibition; Costimulation; Solid tumors; Targeted therapy |
| 413 | Poster Presentation | GEN-009, a personalized neoantigen vaccine, elicits robust immune responses in individuals with advanced or metastatic solid tumors | Mara G. Shainheit, PhD; Devin P. Champagne; Gabriella Santone; Syukri Shukor; Ece Bicak; Samuel Tipps; Li Xue; Thomas A. Davis, MD; Jessica B. Flechtner, PhD; Mara G. Shainheit, PhD; | In-Progress Clinical Trials | Biomarkers; Clinical study; Neoantigens; Solid tumors; T cell; Vaccine |
| 414 | Poster Presentation | Enhancing T cell therapy for patients with relapsed/refractory Wilms Tumor | Amy Hont, MD; Conrad R. Cruz; Maja Stanojevic; Robert Ulrey; Madeline Terpilowski; Emily Reynolds; Fahmida Hoq; Maria F. Fortiz; Haili Lang; Jeffrey S. Dome; Patrick J. Hanley; Catherine Bollard, MD; Holly J. Meany; | In-Progress Clinical Trials | Adoptive immunotherapy; Clinical trial; Immune monitoring; Pediatric tumors; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| 415 | Poster Presentation | Toripalimab plus nab-paclitaxel and carboplatin as neoadjuvant therapy for patients with esophageal squamous cell carcinoma at clinical stage T2-T4/N0-N2/M0: a single-arm, single-center clinical study | Kunkun Li, MD; Xiao Yang; Wei Luo; Qiang Ma; Yingjian Wang; Yanli Xiong; Xiaolong Zhao; Xianfeng Lu; Tao Bao; Wei Guo; Mengxia Li; | In-Progress Clinical Trials | Checkpoint blockade; Chemotherapy; Clinical study; Surgery |
| 416 | Poster Presentation | SQ3370-001 is a multi-center open-label phase I dose-escalation study to test a novel intratumoral and systemic approach to treat advanced solid tumors | Vivek Bhadri, MD; Nam Bui, MD; Alexander Guminski, MD; Jose M. Mejia Oneto, MD, PhD; Ravi Murthy, MD; Kamalesh Sankhala, MD; M. Wayne Saville, MD; M. Wayne Saville, MD; M. Wayne Saville, MD; Sangeetha Srinivasan, PhD; Robert Steffner, MD; Vivek Subbiah, MD; Ding Wang, MD; Nathan A. Yee, PhD; | In-Progress Clinical Trials | Chemotherapy; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 417 | Poster Presentation | Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors | Gregory A. Durm, MD; Sophia Frentzas; Erik Rasmussen; Saltanat Najmi; Nooshin H. Sadraei; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Cytokine; Solid tumors |
| 418 | Poster Presentation | A Phase 1, Dose Escalation and Dose Expansion Study of SQZ PBMC HPV as Monotherapy and in Combination with Atezolizumab in HLA-A*02+ Patients with HPV16+ Recurrent, or Metastatic Solid Tumors. | Cathy Eng, MD; Joaquina C. Baranda, MD; Matthew H. Taylor; Michael S. Gordon; Ursula A. Matulonis, MD; Filip Janku, MD, PhD; Martin Kornacker, MD; Asha Kamat, PhD; Oliver Rosen; Antonio Jimeno, MD, PhD; Cathy Eng, MD; | In-Progress Clinical Trials | Adoptive immunotherapy; Antigen presenting cells; Biomarkers; Clinical study; T cell; Tumor infiltrating lymphocytes (TILs); Vaccine |
| 419 | Poster Presentation | Pharmacodynamic biomarkers demonstrate T-cell activation in patients treated with the oral PD-L1 inhibitor INCB086550 in a phase 1 clinical trial | Sarina A. Piha-Paul, MD; Tara C. Mitchell, MD; Solmaz Sahebjam, MD; Janice M. Mehnert, M.D.; Thomas Karasic; Kevin O’Hayer; Ryan Geschwindt, BS; Susan Spitz, PhD; Hao Liu, PhD; Johanna C. Bendell, MD; Sarina A. Piha-Paul, MD; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Inflammation; Solid tumors; T cell |
| 420 | Oral Presentation | Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study | Adi Diab, MD; Scott S. Tykodi, MD, PhD; Gregory A. Daniels, MD, PhD; Michele Maio, MD; Brendan D. Curti, MD; Karl D. Lewis, MD; Sekwon Jang, MD; Ewa Kalinka, PhD, MD; Igor Puzanov, MD, MSCI; Alexander I. Spira, MD, PhD, FACP; Daniel C. Cho, MD; Shanhong Guan, PhD; Erika Puente, MD; Ute Hoch, PhD; Sue L. Currie, PhD; Tuan Nguyen, PhD; Wei Lin, MD; Mary A. Tagliaferri, MD; Jonathan Zalevsky, PhD; Mario Sznol, MD; Michael E. Hurwitz, MD, PhD; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Cytokine; Solid tumors; T cell |
| 421 | Poster Presentation | Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors | Francesca Aroldi, MD; Joseph Sacco, MSc, MBChB, MRCP, Ph; Kevin Harrington, PhD, FRCP, FRCR; Anna C. Olsson-Brown, MD; Pablo Nanclares, MD; Lavita Menezes; Praveen K. Bommareddy, MS, PhD; Suzanne Thomas, PhD; Howard L. Kaufman, MD; Selda Samakoglu, MD, PhD; Mark R. Middleton, MD, PhD; Robert S. Coffin, PhD; | In-Progress Clinical Trials | Antibody; Antigen presenting cells; Checkpoint blockade; Clinical trial; Dendritic cell; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 422 | Poster Presentation | An Open-label, multicenter, Phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: Updated results from the skin cancer cohorts | Mark R. Middleton, MD, PhD; Francesca Aroldi, MD; Joseph Sacco, MSc, MBChB, MRCP, Ph; Mohammed M. Milhem, MBBS; Brendan D. Curti, MD; Ari M. VanderWalde, MD, MPH, MBioeth; Scott Baum, MD; Adel Samson, MBChB, PhD; Anna C. Pavlick, MD, MBA; Jason A. Chesney, MD; Jiaxin Niu, MD; Terence Rhodes, MD, PhD; Tawnya L. Bowles, MD; Robert M. Conry, MD; Anna C. Olsson-Brown, MD; Douglas Earl Laux, MD; Howard L. Kaufman, MD; Praveen K. Bommareddy, MS, PhD; Alex Deterding; Selda Samakoglu, MD, PhD; Robert S. Coffin, PhD; Kevin Harrington, PhD, FRCP, FRCR; | In-Progress Clinical Trials | Clinical trial; Solid tumors; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Vaccine |
| 423 | Poster Presentation | Safety and preliminary efficacy of intratumoral cavrotolimod (AST-008), a spherical nucleic acid TLR9 agonist, in combination with pembrolizumab in patients with advanced solid tumors | Steven J. O'Day, MD; Cesar A. Perez, MD; Trisha M. Wise-Draper, MD, PhD; Glenn J. Hanna, MD; Shailender Bhatia, MD; Ciara Kelly, MD; Theresa Medina, MD; Douglas E. Laux, MD; Adil Daud, MD; Sunandana Chandra, MD; Montaser F. Shaheen, MD; Ling Gao, MD; Melissa Burgess, MD; Leonel Hernandez-Aya, MD; Cecilia CS. Yeung, MD; Kimberly Smythe, PhD; Emil M. DeGoma, MD; Weston L. Daniel, PhD; Douglas E. Feltner, MD; Laurel Sindelar; Robert E. Michel, PhD; Alice S. Bexon, MD; Martin Bexon, MD; Mohammed M. Milhem, MBBS; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; TLR; Tumor microenvironment |
| 425 | Poster Presentation | Investigation of Wnt Ligand Signaling Regulators as a Predictor of Anti-PD-1 Response in Metastatic Melanoma | Nicholas DeVito, MD; Michael Sturdivant, B.S.; Luke P. Wachsmuth, B.S.; John H. Strickler, MD; Georgia M. Beasley, MD, MHs; Rami Al-Rohil; April Salama, MD; Brent A. Hanks, MD, PhD; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Clinical trial; Dendritic cell; Gene expression; Immune suppression; Immune tolerance; Solid tumors; Tumor evasion; RNA |
| 426 | Poster Presentation | MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma | Reinhard Dummer, MD; Georgina V. Long, BSc, PhD, MB, BS, FRACP; Anna Pavlick, DO; Michael Postow, MD; Antoni Ribas, MD, PhD; Caroline Robert, MD, PhD; Richard A. Scolyer, BMedSci, MBBS, MD, FRCPA, FRCPath; Janis M. Taube, MD; Michael Tetzlaff, MD, PhD; Jason Liao, PhD; Sama Ahsan, MD; Scott J. Diede, MD, PhD; Hussein A. Tawbi, MD, PhD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| 427 | Poster Presentation | A Phase 1b/2 Study of Cabozantinib in Combination with Pembrolizumab in Advanced Melanoma | Jayanshu Jain, MD; Melanie Frees; Hesham Yasin; Jaime Bonner; Michele Freesmeier; Rohan Garje; Vyshak Alva Venur, MD; Mohammed M. Milhem, MBBS; Yousef Zakharia, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Targeted therapy |
| 428 | Poster Presentation | Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs) | Karl D. Lewis, MD; Ketty Peris, MD; Alexander J. Stratigos, MD, PhD; Lara A. Dunn, MD; Zeynep Eroglu, MD; Anne Lynn S. Chang, MD; Michael R. Migden, MD; Siyu Li, PhD; Kosalai Mohan, PhD; Ebony Coates, MHA; Emmanuel Okoye, MBBS, MPH; Jean-François Baurain, MD, PhD; Oliver Bechter, MD; Axel Hauschild, MD; Marcus O. Butler, MD; Leonel Hernandez-Aya, MD; Lisa Licitra, MD; Rogerio I. Neves, MD PhD FACS; Emily S. Ruiz, MD; Frank Seebach, MD; David M. Weinreich, MD; George D. Yancopoulos, MD, PhD; Israel Lowy, MD, PhD; Timothy Bowler, MD, PhD; Matthew G. Fury, MD, PhD; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical trial |
| 429 | Poster Presentation | Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma | Georgina V. Long, MBBS, PhD, BSc, FRAC; Reinhard Dummer, MD; Douglas B. Johnson, M.D.; Olivier Michielin, MD PhD; Salvador Martin-Algarra; Sheryl A. Treichel; Edward L. Chan; Scott J. Diede, MD, PhD; Antoni Ribas, MD, PhD; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; Targeted therapy |
| 430 | Poster Presentation | A phase II study of nivolumab + BMS-986016 (relatlimab) in patients with metastatic uveal melanoma(UM) (CA224-094) | Jose Lutzky, MD, FACP; Lynn Feun, MD; William J. Harbour, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Coinhibition; Solid tumors; T cell |
| 431 | Poster Presentation | Prospective, randomized trial of the tumor lysate, particle only vaccine compared to the tumor lysate, particle-loaded, dendritic cell vaccine to prevent recurrence for resected stage III/IV melanoma | Patrick M. McCarthy, MD; Lexy M. Adams, MD, MPH; Robert C. Chick, M.D.; Guy T. Clifton, MD; Timothy J. Vreeland, BS MD; Anne E. O'Shea, MD; Phillip M. Kemp Bohan, MD; Annelies T. Hickeron, MD; Jessica L. Campf, MD; John W. Myers, MD; Tommy A. Brown, MD; Diane F. Hale, MD; Mark B. Faries, MD; John Hyngstrom, MD; Adam C. Berger, FACS, MD; James W. Jakub, MD; Jeffrey J. Sussman, MD; Montaser F. Shaheen, MD; Thomas E. Wagner, BS, MD; George E. Peoples, MD, FACS; | In-Progress Clinical Trials | Antigen presenting cells; Clinical study; Clinical trial; Dendritic cell; Solid tumors; Surgery; Targeted therapy; Vaccine; Extracellular vesicles/exosomes |
| 432 | Poster Presentation | 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma | Reinhard Dummer, MD; David E. Gyorki; John Hyngstrom, MD; Adam C. Berger, FACS, MD; Robert M. Conry, MD; Lev Demidov, MD, DSc; Edward L. Chan; Hoi-Shen Radcliffe; Mark B. Faries, MD; Merrick Ross, MD; | In-Progress Clinical Trials | Clinical trial; Solid tumors; Surgery |
| 433 | Poster Presentation | Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial | Igor Puzanov, MD, MSCI; Jason A. Chesney, MD; Frances A. Collichio, MD; Parminder Singh, MD; Mohammed M. Milhem, MBBS; John Glaspy, MD; Omid Hamid, MD; Merrick Ross, MD; Philip Friedlander, MD PhD; Claus Garbe, MD, PhD; Theodore F. Logan, MD; Axel Hauschild, MD; Celeste Lebbe; Min Yi; Wendy Snyder; Janice M. Mehnert, M.D.; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Solid tumors |
| 434 | Poster Presentation | Updated clinical data from the melanoma expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab | Michael Postow, MD; Ryan J. Sullivan, MD; Ezra EW. Cohen, MD; Martin Gutierrez, MD; David S. Hong, MD; Conor Steuer, MD; Jerry McCarter, RN, BSN; Nora Zizlsperger; Jeff Kutok, MD, PhD; Brenda O'Connell, PhD; Jennifer Roberts; Kara Page; Halle Zhang, PhD; Bartosz Chmielowski, MD, PhD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Immune suppression; Immune tolerance; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor microenvironment |
| 435 | Poster Presentation | A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma | Saba S. Shaikh, MD; Yan Zang, MS; Hong Wang, PhD; Xi Yang, BS; Cindy Sander; Amy Rose; Diwakar Davar, MD; Jason J. Luke, MD; Hassane M. Zarour, MD; John M. Kirkwood, MD; Greg M. Delgoffe, PhD; Yana G. Najjar, MD; | In-Progress Clinical Trials | Angiogenesis; Checkpoint blockade; Clinical trial; Metabolism; Solid tumors; Targeted therapy; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 798 | Poster Presentation | Safety, Tolerability, and Immunogenicity of mRNA-4157 in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603): an Update | Julie E. Bauman, MD, MPH; Manish Patel, MD; Daniel C. Cho, MD; Martin Gutierrez, MD; Ricklie A. Julian; Aaron Scott, MD; Pamela S. Cohen, MD; Joshua Frederick, PhD; Celine Robert-Tissot; Honghong Zhou, PhD; Kinjal Mody; Karen Keating; Robert S. Meehan, MD; Justin F. Gainor, MD; | In-Progress Clinical Trials | RNA; Clinical study; Clinical trial; Neoantigens; Solid tumors; Tumor antigens; Vaccine |
| 799 | Poster Presentation | Durable responses and immune activation with intratumoral electroporation of pIL-12 plus pembrolizumab in actively progressing anti-PD-1 refractory advanced melanoma: KEYNOTE 695 interim data | Pablo Fernandez-Penas, MD, PhD; Matteo S. Carlino, M.D., Ph.D.; Katy K. Tsai, MD; Victoria G. Atkinson, MD; Monaster Shaheen, MD; Sajeve Thomas, MD; Catalin Mihalcioiu, MD, FRCP; Tom Van Hagen, MD; Rachel Roberts-Thomson, MD; Andrew Haydon, M.D., Ph.D.; Andrew Mant, MD; Marcus O. Butler, MD; Gregory A. Daniels, MD, PhD; Elizabeth I. Buchbinder, MD; John Hyngstrom, MD; Mecker Moller, MD, FACS; Igor Puzanov, MD, MSCI; C. Lance Cowey, MD; Eric D. Whitman, MD, FACS; Carmen Ballesteros-Merino, PhD; Shawn M. Jensen, PhD; Bernard A. Fox, PhD; Emmett V. Schmidt, MD PhD; Clemens Krepler, MD; Scott J. Diede, MD, PhD; Erica Browning; Reneta Hermiz; Lauren Svenson; Jon Salazar; Jack Lee, BS, MS; Christopher Baker; Donna Bannavong; Jendy Sell; Kellie Malloy Foerter; David A. Canton, PhD; Sandra Aung, PhD; Christopher G. Twitty, PhD; Alain P. Algazi, MD; Adil Daud, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Cytokine; Gene expression; Immune adjuvant; Immune monitoring; T cell; Tumor microenvironment |
| 800 | Poster Presentation | A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors | Thomas Eigentler, MD; Lucie Heinzerling; Jürgen Krauss; Carsten Weishaupt; Peter Mohr; Sebastian Ochsenreither; Patrick Terheyden; Juan Martin-Liberal; Marc Oliva; Céleste Lebbe; Michael Fluck; Peter Brossart; Jose Manuel Trigo Perez, MD, PhD; Franz-Georg Bauernfeind, Dr; Sarah-Katharina Kays; Tobias Seibel, II; Oliver Schönborn-Kellenberger; Claudia Stosnach; Angelika Daehling; Beate Schmitt-Bormann; Ulrike Gnad-Vogt, MD; | In-Progress Clinical Trials | RNA; Clinical study; Clinical trial; Solid tumors; TLR |
| 801 | Poster Presentation | PRIME™ IL-15 (RPTR-147): Preliminary clinical results and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients | Erika P. Hamilton, MD; Sarah Nikiforow; Philip D. Bardwell, PhD; Christine M. McInnis, PhD; Jeffrey Zhang; George R. Blumenschein, Jr., MD; Mihaela Cristea, MD; Keren Osman; Anthony F. Shields, MD PhD; Marlyane Motta; Sanela Bilic; Oliver Schoenborn-Kellenberger; James A. Rakestraw; Shawn P. Carey, PhD; Elena Geretti, PhD; Karsten Sauer; Tim Harris, PhD, D.Sc; Tap Maniar, MD; Becker Hewes, MD; Thomas Andresen, PhD; Jonathan B. Fitzgerald, PhD; Harriet Kluger, MD; | In-Progress Clinical Trials | Adoptive immunotherapy; Biomarkers; Clinical study; Clinical trial; Cytokine; Solid tumors; T cell; Tumor antigens |
| 802 | Poster Presentation | Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint blockade | Brett H. Herzog, MD, PhD; Saiama Waqar, MD; Siddhartha Devarakonda, MD; Jeffrey Ward, MD, PhD; Ramaswamy Govindan, MD; Daniel Morgensztern, MD; | In-Progress Clinical Trials | Angiogenesis; Checkpoint blockade; Clinical trial; Immune contexture; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 803 | Poster Presentation | Phase 1/2 study using ENB-003, a first-in-class selective ETBRi, in combination with pembrolizumab in subjects with advanced refractory solid tumors | Adnan Nagrial, MD; Sumayah Jamal, MD-PhD; Anthony M. Joshua, MD; Richard W. Eek, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 804 | Poster Presentation | A Phase II study of the anti-programmed cell death-1 (PD-1) antibody Penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy | Xiaozhong Chen; Wei Wang; Qingfeng Zou; Jingao Li; Chaosu Hu, MD; Chaosu Hu, MD; Qin Lin; Xiaodong Zhu; Yi Jiang; Yan Sun; Liangfang Shen; Lin Wang; Guorong Zou; Xiaoyan Lin; Ying Wang; Shaojun Lin; Minying Li; Rui Ao; Ruilian Xu; Haifeng Lin; Rensheng Wang; Jiacheng Yang; Weifeng Song; Max Wang; Baiyong Li, PhD; Yu Xia, PhD; | In-Progress Clinical Trials | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune toxicity; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| 805 | Poster Presentation | Safety and emerging evidence of immune modulation of the live biotherapeutic MRx0518 in the neoadjuvant setting for patients awaiting surgical removal of solid tumours | Mark Lythgoe, MBBS, MRPharmS; Justin Stebbing; Emily Pickford; Axel Glasmacher; Marsilio Adriani, PhD; Gayle L. Fyvie; Adam Frampton; Alex Stevenson; Jonathan Krell, PhD, MRCP, MBChB, BSc; | In-Progress Clinical Trials | Clinical study; Clinical trial; Microbiome; Solid tumors; Tumor infiltrating lymphocytes (TILs); TLR |
| 806 | Poster Presentation | Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer | Luis Manso; Patricia Villagrasa, PhD; Nuria Chic; Begoña Bermejo; Juan M. Cejalvo; Yann Izarzugaza; Blanca Cantos; Salvador Blanch; Mireia Margeli; Jose L. Alonso; Alejandro Martínez; Rafael Villanueva; Juan Guerra; Raquel Andrés; Pilar Zamora; Esteban Nogales; Manel A. Juan; Blanca Gonzalez-Farre; Thomas C. Heineman; Gerard Nuovo; Grey A. Wilkinson, PhD; Matt Coffey, PhD; Azucena Gonzalez; Débora Martínez; Laia Paré; Fernando Salvador; Xavier Gonzalez; Aleix Prat, MD PhD; Joaquín Gavilá; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Clinical trial; Immune adjuvant; Inflammation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 807 | Poster Presentation | A multicenter open-label phase I/lb study of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors | Aurelien Marabelle, MD, PhD; Stephane Champiat; Elena Garralda, MD; Alberto Hernando; Filip Janku, MD, PhD; Anjali Raina; Richard Sachse; David Bechard; Inna Krasnopolskaya; Stefano Ferrara; Patricia LoRusso, DO; | In-Progress Clinical Trials | Cytokine; NK/NK T cell; T cell lineages |
| 808 | Poster Presentation | Exploring resistance mechanism to pembrolizumab and ang-2 inhibitor trebananib (NCT03239145) using high-dimensional single-cell mass cytometry (CyTOF) | Osama E. Rahma, MD; Joanna Baginska, PhD; Martha Brainard; Anita Giobbie-Hurder, MS; Kevin Tyan, BA; James Cleary; Benjamin Schlechter; Anna K. Maloney; Michael P. Manos, BA; Rizwan Romee, MD; Mariano Severgnini, MSc; F. Stephen Hodi, Jr., MD; | In-Progress Clinical Trials | Angiogenesis; Antibody; Checkpoint blockade; Clinical trial; Monocyte/Macrophage; Myeloid cells; NK/NK T cell; T cell; T cell lineages; Targeted therapy |
| 809 | Poster Presentation | Phase 2 trial of neoadjuvant and adjuvant PD-1 checkpoint blockade in local-regionally advanced, resectable HNSCC indicates pathological response is associated with high disease-free survival | Trisha M. Wise-Draper, MD, PhD; Shuchi Gulati, MD, FACP; Vinita Takiar; Sarah Palackdharry; Francis P. Worden, MD; Matthew Old, MD; John M. Kaczmar, MD; Neal Dunlap, MD; Benjamin Hinrichs, MD; Diana Bell; Yash Patil; Muhammad Kashif Riaz, MD; Layne Weatherford, PhD; Aubrey Hamilton; Sheena Lanverman; Michelle Mierzwa; Keith Casper; Jonathan Mark; Alice Tang; Chad Zender; Ann Gillenwater; Mario Medvedovich; J. Jack Lee, PhD; Roman Jandarov; Maura L. Gillison, MD, PhD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; T cell |
| 810 | Poster Presentation | Preliminary Safety, Tolerability and Efficacy Results of KN026 in combination with KN046 in Patients with HER2 aberrated solid tumors | Jifang Gong, MD; Lin Shen, MD,PhD; Jifang Gong, MD; Zhi Dong; Dan Liu; June Xu; Jing Yang; Yue Yang; Yakun Qi; Jie Men; Paul Kong; Ting Xu; | In-Progress Clinical Trials | Bispecifics; Checkpoint blockade; Solid tumors |
| 812 | Oral Presentation | Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer | Lei Zheng, PhD MD; Carol Judkins; Jessica Hoare; Rachel Klein; Rose Parkinson; Hao Wang; Haihui Cao; Jennifer Durham; Katrina Purtell; Ana De Jesus-Acosta; Dung T. Le, MD; Amol Narang; Robert A. Anders, MD, PhD; Richard Burkhart; William Burns; Christopher Wolfgang; Elizabeth D. Thompson, MD PhD; Daniel A. Laheru; Jin He, MD, PhD; Elizabeth M. Jaffee, MD; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical study; Costimulation; Solid tumors; Surgery; T cell; Tumor microenvironment; Vaccine |
